Literature DB >> 25082788

Reply to "The challenge of cross-trial comparison using limited data" Haematologica. 2014;99(8):e000.

David S Siegel1.   

Abstract

Keywords:  challenge; cross-trial; data

Mesh：

Substances：

Year:  2014        PMID： 25082788      PMCID： PMC4116849          DOI： 10.3324/haematol.2014.112482

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  7 in total

1.  The challenge of cross-trial comparisons using limited data.

Authors:  Jacob P Laubach; Edward A Faber; Peter Voorhees; Javid Moslehi; Cindy Varga; Liviu Niculescu; Kenneth C Anderson; Paul G Richardson
Journal:  Haematologica       Date:  2014-08       Impact factor: 9.941

2.  An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Authors:  Ravi Vij; Michael Wang; Jonathan L Kaufman; Sagar Lonial; Andrzej J Jakubowiak; A Keith Stewart; Vishal Kukreti; Sundar Jagannath; Kevin T McDonagh; Melissa Alsina; Nizar J Bahlis; Frederic J Reu; Nashat Y Gabrail; Andrew Belch; Jeffrey V Matous; Peter Lee; Peter Rosen; Michael Sebag; David H Vesole; Lori A Kunkel; Sandra M Wear; Alvin F Wong; Robert Z Orlowski; David S Siegel
Journal:  Blood       Date:  2012-05-03       Impact factor: 22.113

3.  An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

Authors:  Ravi Vij; David S Siegel; Sundar Jagannath; Andrzej J Jakubowiak; Alexander Keith Stewart; Kevin McDonagh; Nizar Bahlis; Andrew Belch; Lori A Kunkel; Sandra Wear; Alvin F Wong; Michael Wang
Journal:  Br J Haematol       Date:  2012-07-30       Impact factor: 6.998

4.  An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

Authors:  Sundar Jagannath; Ravi Vij; A Keith Stewart; Suzanne Trudel; Andrzej J Jakubowiak; Tony Reiman; George Somlo; Nizar Bahlis; Sagar Lonial; Lori A Kunkel; Alvin Wong; Robert Z Orlowski; David S Siegel
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-10

5.  A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Authors:  David S Siegel; Thomas Martin; Michael Wang; Ravi Vij; Andrzej J Jakubowiak; Sagar Lonial; Suzanne Trudel; Vishal Kukreti; Nizar Bahlis; Melissa Alsina; Asher Chanan-Khan; Francis Buadi; Frederic J Reu; George Somlo; Jeffrey Zonder; Kevin Song; A Keith Stewart; Edward Stadtmauer; Lori Kunkel; Sandra Wear; Alvin F Wong; Robert Z Orlowski; Sundar Jagannath
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

6.  Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

Authors:  David Siegel; Thomas Martin; Ajay Nooka; R Donald Harvey; Ravi Vij; Ruben Niesvizky; Ashraf Z Badros; Sundar Jagannath; Leanne McCulloch; Kanya Rajangam; Sagar Lonial
Journal:  Haematologica       Date:  2013-08-09       Impact factor: 9.941

7.  Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.

Authors:  A Z Badros; R Vij; T Martin; J A Zonder; L Kunkel; Z Wang; S Lee; A F Wong; R Niesvizky
Journal:  Leukemia       Date:  2013-01-31       Impact factor: 11.528
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.